Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Combined Therapeutics Inc. operates in the Biotechnology & Pharmaceuticals technology area and currently has 2 pending office actions. These actions are distributed across 2 distinct examiners, which indicates that the portfolio's pending applications are being reviewed by different individuals. The involvement of 2 distinct art units further suggests that the technology being patented spans multiple specialized areas of biotechnology. This distribution requires a coordinated prosecution effort to maintain consistency across different examination groups.
The busiest examiner for this portfolio is QIAN, CELINE X, who is responsible for 1 busiest examiner pending office action. With a total of 2 pending office actions, the workload is split among the 2 distinct examiners. This balance means that the company's patent prospects are not tied to the decisions of just one person. However, the 2 distinct art units may have different examination speeds, which could result in staggered timelines for the pending applications.
The 2 pending office actions within the Biotechnology & Pharmaceuticals sector highlight the company's active pursuit of patent protection. Because the examiners are located in separate art units, the legal team must be prepared to address a variety of technical and procedural challenges. This multi-track prosecution strategy allows the company to build a more comprehensive portfolio by engaging with different specialized units at the USPTO.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| QIAN, CELINE X | 1 | 47.5% | +17.2% |
| CORDAS, EMILY ANN | 1 | 50.9% | +57.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16970888 | COMPOSITIONS AND METHODS FOR ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS | CORDAS, EMILY ANN | 27d |
| 18018759 | COMPOSITIONS AND METHODS FOR IMPROVED VACCINATION | QIAN, CELINE X | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18018759 | COMPOSITIONS AND METHODS FOR IMPROVED VACCINATION | QIAN, CELINE X | 1637 | §102§103DP | Final Rejection | — | Pending | Jan 30, 2023 |
| 16970888 | COMPOSITIONS AND METHODS FOR ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDS | CORDAS, EMILY ANN | 1632 | §103 | Final Rejection | 27d | Pending | Aug 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCombined Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Celine X Qian has the most, with 1 of Combined Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
